umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The HCV life cycle: in vitro tissue culture systems and therapeutic targets
TWINCORE – Institute of Experimental Virology, Centre for Experimental and Clinical Infection Research, Hannover , Germany. (Gisa Gerold)
2014 (engelsk)Inngår i: Digestive Diseases, ISSN 0257-2753, E-ISSN 1421-9875, Vol. 32, nr 5, s. 525-537Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Hepatitis C virus (HCV) is a highly variable plus-strand RNA virus of the family Flaviviridae. Viral strains are grouped into six epidemiologically relevant genotypes that differ from each other by more than 30% at the nucleotide level. The variability of HCV allows immune evasion and facilitates persistence. It is also a substantial challenge for the development of specific antiviral therapies effective across all HCV genotypes and for prevention of drug resistance. Novel HCV cell culture models were instrumental for identification and profiling of therapeutic strategies. Concurrently, these models revealed numerous host factors critical for HCV propagation, some of which have emerged as targets for antiviral therapy. It is generally assumed that the use of host factors is conserved among HCV isolates and genotypes. Additionally, the barrier to viral resistance is thought to be high when interfering with host factors. Therefore, current drug development includes both targeting of viral factors but also of host factors essential for virus replication. In fact, some of these host-targeting agents, for instance inhibitors of cyclophilin A, have advanced to late stage clinical trials. Here, we highlight currently available cell culture systems for HCV, review the most prominent host-targeting strategies against hepatitis C and critically discuss opportunities and risks associated with host-targeting antiviral strategies.

sted, utgiver, år, opplag, sider
S. Karger, 2014. Vol. 32, nr 5, s. 525-537
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-148160DOI: 10.1159/000360830ISI: 000339145500006PubMedID: 25034285OAI: oai:DiVA.org:umu-148160DiVA, id: diva2:1210797
Tilgjengelig fra: 2018-05-29 Laget: 2018-05-29 Sist oppdatert: 2018-10-11bibliografisk kontrollert

Open Access i DiVA

fulltext(20895 kB)61 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 20895 kBChecksum SHA-512
68f18888f5da65ef7912349f0a016a0e727dd1af5239a5440f51d4965f96fd93294b4840efd006381e5b6b0841cd72e90f2da4ad7aedec9b52ab06600e6229c0
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Gerold, Gisa

Søk i DiVA

Av forfatter/redaktør
Gerold, Gisa
I samme tidsskrift
Digestive Diseases

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 61 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 183 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf